Seven-, ten-, fourteen-day vonoprazan dual therapies for first line treatment of Helicobacter pylori infection in China: A multicenter, three-arm, non-inferiority, randomised clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082170

Enrollment

Unknown

Registered

2024-03-22

Start date

2024-04-15

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

helicobacter pylori infection

Interventions

VHA-7d:Venolazan 20mg once a day and amoxicillin 1g 3 times a day were taken for 7 days

VHA-10d:Venolazan 20mg once a day and amoxicillin 1g 3 times a day were taken for 10 days

VHA-14d:Venolazan 20mg once a day and amoxicillin 1g 3 times a day were taken for 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Subjects aged 18-75 years with H.pylori infection confirmed by carbon 13-breath test (UBT) were recruited.

Exclusion criteria

Exclusion criteria: History of H.pylori eradication therapy, allergy to study drugs (VPZ, AMX), use of PPIs, VPZ, bismuth, and antibiotics in the 4 weeks prior to study.

Design outcomes

Primary

Measure	Time frame
C13 breath test;	—

Secondary

Measure	Time frame
ADRs and compliance;Intestinal flora;	—

Countries

China

Contacts

Public ContactKa Shing Cheung

The University of Hong-Kong-Shenzhen Hospital

cks634@hku.hk+86 183 0755 6165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026